NYSE:SNY
Sanofi Stock News
$50.21
+0.93 (+1.89%)
At Close: May 13, 2024
GlaxoSmithKline and Sanofi plan to join vaccine race with booster doses
09:08am, Monday, 17'th May 2021
GlaxoSmithKline PLC (LON:GSK) and Sanofi are planning to join the vaccine race well after their competitors as they pin their hopes on the need for boosters. The pair have received lukewarm market rea
Sanofi, GSK Covid Vaccine Triggers ‘Strong Immune Response' As Firms Aim For Approval Later This Year
08:21am, Monday, 17'th May 2021
A Phase 3 trial to test the vaccine's efficacy is expected to start in a matter of weeks, with the vaccine showing potential to be a booster shot.
Sanofi-GSK's COVID-19 Vaccine Candidate Reports Success In Mid-Stage Study
07:07am, Monday, 17'th May 2021
Sanofi SA (NASDAQ: SNY) and its collaborating partner GlaxoSmithKline plc (NYSE: GSK) have reported "strong immune responses" in early tests of their COVID-19 vaccine, raising hopes it could join
GSK and Sanofi reveal positive trial results for COVID-19 vaccine
03:33am, Monday, 17'th May 2021
GlaxoSmithKline PLC (LON:GSK) announced that the COVID-19 vaccine developed with French giant Sanofi demonstrated strong immune responses in mid-stage trials. The jab showed 95% to 100% seroconversion
GlaxoSmithKline, Sanofi post positive mid-stage trial results for COVID-19 vaccine
02:30am, Monday, 17'th May 2021
GlaxoSmithKline PLC (LON:GSK) announced that the COVID-19 vaccine developed with French giant Sanofi demonstrated strong immune responses in mid-stage trials. The jab showed 95% to 100% seroconversion
Sanofi and Glaxo Are Back With a Covid-19 Vaccine
01:30am, Monday, 17'th May 2021
The two drugmakers say it might be most useful as a booster shot.
Is Sanofi a Good Buy in 2021?
06:20am, Wednesday, 12'th May 2021
You might want to add this international blue-chip stock to your portfolio.
Sanofi establishes three-year collaboration with Stanford Medicine to accelerate immunology research
01:00am, Thursday, 06'th May 2021
PARIS and PALO ALTO, Calif., May 6, 2021 /PRNewswire/ -- Sanofi has entered into a three-year research collaboration with Stanford University School of Medicine.
Sanofi (SNY) CEO Paul Hudson on Q1 2021 Results - Earnings Call Transcript
12:45am, Thursday, 29'th Apr 2021
Sanofi (SNY) CEO Paul Hudson on Q1 2021 Results - Earnings Call Transcript
Sanofi Shares Rise On Q1 Sales Boosted By Dupixent Franchise; Plans To Restart Haemophilia Study With Fitusiran
01:27pm, Wednesday, 28'th Apr 2021
Sanofi SA (NASDAQ: SNY) stock climbed after its Q1 earnings beat earnings expectations and stuck to its full-year guidance, as well as reported progress on its delayed COVID-19 vaccine efforts. Ea
Update: 91 'Top Dividend Stocks On Earth' For May
01:18pm, Wednesday, 28'th Apr 2021
Kiplinger "insights for investors" online first offered this list of 91 "Top Dividend Stocks From Around The World" July 13, 2020. Data updated 4/26/21 flagged 13 yields ripe with upside. These Intern
Sanofi (SNY) Q1 Earnings & Sales Beat, Keeps 2021 EPS View
12:17pm, Wednesday, 28'th Apr 2021
Sanofi's (SNY) Q1 earnings and sales beat estimates. Dupixent drives sales growth in the quarter.
Sanofi Beats Earnings Estimates and Reveals Covid-19 Vaccine Progress
07:03am, Wednesday, 28'th Apr 2021
The French pharma giant, which has fallen behind in the Covid-19 vaccine race, said results from a Phase 2 study into its candidate with GlaxoSmithKline are expected next month.
Eczema treatment and vaccines lift Sanofi first quarter results
03:11am, Wednesday, 28'th Apr 2021
Sanofi confirmed its 2021 targets after it posted stronger-than-expected first quarter results as sales of its star eczema treatment as well as flu and polio vaccines helped offset a dip in cough and
Sanofi Steps In For Fill-Finish 200M Doses Of Moderna's COVID-19 Vaccine
09:18am, Monday, 26'th Apr 2021
As the demand for mRNA-based COVID-19 vaccines persists, Sanofi SA (NASDAQ: SNY) has entered an agreement with Moderna Inc (NASDAQ: MRNA) to manufacture its COVID-19 vaccine in the U.S. The ag
